Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTSO Cytosorbents	$0.91 +8.2%	$1.06	$0.71 ▼ $1.61	$52.97M	1.19	369,540 shs	349,614 shs
IRIX IRIDEX	$1.24 +2.5%	$1.14	$0.78 ▼ $2.04	$20.56M	0.62	138,956 shs	120,280 shs
NTRB Nutriband	$6.43 +1.9%	$7.70	$3.72 ▼ $11.78	$70.38M	1.13	194,205 shs	20,503 shs
VANI Vivani Medical	$1.24 +2.5%	$1.35	$0.91 ▼ $1.80	$71.68M	2.99	149,919 shs	29,316 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTSO Cytosorbents	-5.58%	-25.96%	-15.60%	-0.12%	-20.38%
IRIX IRIDEX	-5.47%	+8.04%	-12.32%	+23.47%	-39.20%
NTRB Nutriband	+1.45%	+0.16%	-27.22%	+15.15%	+9.59%
VANI Vivani Medical	-0.82%	-4.72%	-22.44%	+7.08%	-12.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTSO Cytosorbents	2.1581 of 5 stars	3.3	3.0	2.6	0.0	0.6
IRIX IRIDEX	1.6302 of 5 stars	0.0	5.0	3.6	1.7	0.0
NTRB Nutriband	3.5531 of 5 stars	3.5	5.0	3.3	1.7	0.6
VANI Vivani Medical	2.4431 of 5 stars	3.5	3.0	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTSO Cytosorbents	2.50	Moderate Buy	$5.50	502.34% Upside
IRIX IRIDEX	0.00	N/A	N/A	N/A
NTRB Nutriband	3.00	Buy	$13.00	101.86% Upside
VANI Vivani Medical	3.00	Buy	$4.00	222.58% Upside

Current Analyst Ratings Breakdown

Latest IRIX, VANI, NTRB, and CTSO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/8/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/21/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTSO Cytosorbents	$35.60M	1.61	N/A	N/A	$0.18 per share	5.07
IRIX IRIDEX	$48.67M	0.43	N/A	N/A	N/A	∞
NTRB Nutriband	$2.14M	33.55	N/A	N/A	$0.58 per share	11.10
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTSO Cytosorbents	-$20.72M	-$0.17	N/A	N/A	N/A	-25.58%	-111.97%	-29.00%	11/6/2025 (Estimated)
IRIX IRIDEX	-$8.91M	-$0.33	N/A	∞	N/A	-10.95%	-386.93%	-17.42%	N/A
NTRB Nutriband	-$10.48M	-$0.90	N/A	N/A	N/A	-415.93%	-68.25%	-60.40%	9/2/2025 (Estimated)
VANI Vivani Medical	-$23.49M	-$0.45	N/A	N/A	N/A	N/A	-194.66%	-68.64%	N/A

Latest IRIX, VANI, NTRB, and CTSO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	N/A	NTRB Nutriband	-$0.17	N/A	N/A	N/A	$0.71 million	N/A
8/13/2025	Q2 2025	VANI Vivani Medical	-$0.10	-$0.12	-$0.02	-$0.12	N/A	N/A
8/12/2025	Q2 2025	IRIX IRIDEX	-$0.09	-$0.06	+$0.03	-$0.06	$13.10 million	$13.57 million
8/7/2025	Q2 2025	CTSO Cytosorbents	-$0.07	-$0.05	+$0.02	$0.03	$9.79 million	$9.62 million
5/30/2025	Q1 2026	NTRB Nutriband	-$0.13	-$0.12	+$0.01	-$0.12	$0.71 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
IRIX IRIDEX	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTSO Cytosorbents	1.24	2.34	1.96
IRIX IRIDEX	62.29	1.96	1.34
NTRB Nutriband	0.01	3.71	3.48
VANI Vivani Medical	N/A	1.30	1.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTSO Cytosorbents	32.87%
IRIX IRIDEX	20.10%
NTRB Nutriband	19.70%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CTSO Cytosorbents	7.30%
IRIX IRIDEX	7.40%
NTRB Nutriband	54.09%
VANI Vivani Medical	46.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTSO Cytosorbents	220	62.76 million	58.18 million	Optionable
IRIX IRIDEX	120	16.99 million	15.74 million	Optionable
NTRB Nutriband	10	11.15 million	5.12 million	Not Optionable
VANI Vivani Medical	20	59.24 million	31.76 million	Optionable

IRIX, VANI, NTRB, and CTSO Headlines

Recent News About These Companies

Are weight-loss jabs for dogs the next big thing? Scientists exploring new solutions for pet obesity

August 22 at 10:49 AM | msn.com

Ozempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We Know

August 22 at 10:49 AM | msn.com

Could Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet Obesity

August 21 at 11:28 AM | ndtv.comN

After Ozempic, is “Ozempup” on the way? Scientists explore weight-loss jabs for obese pet dogs-- All details here

August 21 at 3:54 AM | msn.com

Vivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant Technology

August 20 at 8:51 AM | quiverquant.comQ

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

August 20 at 8:30 AM | globenewswire.com

Fido get fat? Ozempic for dogs could hit the market in three years

August 19 at 7:29 PM | msn.com

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings Miss

August 15, 2025 | marketbeat.com

Vivani Medical (NASDAQ:VANI) Announces Quarterly Earnings Results

August 15, 2025 | marketbeat.com

Vivani closes $10M financing, advances GLP-1 implant

August 14, 2025 | drugdeliverybusiness.comD

Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% Following Weak Earnings

August 14, 2025 | americanbankingnews.com

Vivani Medical Reports Q2 2025 Results and $10M Financing

August 13, 2025 | tipranks.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...

August 13, 2025 | bakersfield.comB

Vivani Medical Secures $10M Through Share Purchase Agreement

August 13, 2025 | msn.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Growth in Short Interest

August 2, 2025 | marketbeat.com

Vivani Medical (NASDAQ:VANI) Shares Up 0.6% - Here's What Happened

July 23, 2025 | marketbeat.com

3 Penny Stocks With Market Caps Over $30M To Consider

July 16, 2025 | finance.yahoo.com

Vivani Medical Insiders Added US$5.29m Of Stock To Their Holdings

June 30, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRIX, VANI, NTRB, and CTSO Company Descriptions

Cytosorbents NASDAQ:CTSO

$0.91 +0.07 (+8.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.91 0.00 (-0.34%)

As of 05:35 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

IRIDEX NASDAQ:IRIX

$1.24 +0.03 (+2.81%)

As of 04:00 PM Eastern

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Nutriband NASDAQ:NTRB

$6.43 +0.12 (+1.90%)

Closing price 03:59 PM Eastern

Extended Trading

$6.47 +0.04 (+0.56%)

As of 07:57 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Vivani Medical NASDAQ:VANI

$1.24 +0.03 (+2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.40%)

As of 07:42 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time